Skip to content
Search

Latest Stories

Jaguar unveils new logo ahead of electric transition

The new logo, stylised as "JaGUar," combines upper and lower-case letters in what the company describes as "visual harmony."

Owned by Tata Motors, the British automaker plans to release three new electric models in 2026, after halting new car sales over a year ago to focus on rebranding.
Owned by Tata Motors, the British automaker plans to release three new electric models in 2026, after halting new car sales over a year ago to focus on rebranding.

JAGUAR has introduced a new logo and branding as it prepares to relaunch as an electric-only car manufacturer.

Owned by Tata Motors, the British automaker plans to release three new electric models in 2026, after halting new car sales over a year ago to focus on rebranding.


The new logo, stylised as "JaGUar," combines upper and lower-case letters in what the company describes as "visual harmony."

Alongside the logo, Jaguar unveiled a new "leaper" cat design and introduced marketing slogans like "delete ordinary," according to the BBC.

Copy nothing. #Jaguar pic.twitter.com/BfVhc3l09B

— Jaguar (@Jaguar) November 19, 2024

Jaguar's transition to electric vehicles was first announced in 2021. Managing director Rawdon Glover explained that pausing sales was a deliberate decision to separate older models from the upcoming range.

"We need to change people's perceptions of what Jaguar stands for," he said, adding that this "fire break" was necessary for the transformation.

Gerry McGovern, chief creative officer of Jaguar Land Rover (JLR), said the reimagined brand reflects Jaguar’s heritage of originality, as envisioned by founder Sir William Lyons.

McGovern described the new Jaguar identity as "imaginative, bold, and artistic."

The first car in the rebranded line-up will be a four-door GT, set to be built in Solihull, West Midlands.

More For You

pharmacy

The UK spends just 9 per cent of healthcare budgets on medicines while patients face growing access gaps.

iStock

UK calls for new pharmaceutical investment to strengthen life sciences

Highlights

  • UK life sciences sector contributed £17.6bn GVA in 2021 and supports 126,000 high-skilled jobs.
  • Inward life sciences FDI fell by 58 per cent from £1,897m in 2021 to £795m in 2023.
  • Experts warn NHS underinvestment and NICE pricing rules are deterring innovation and patient access.

Investment gap

Britain is seeking to attract new pharmaceutical investment as part of its plan to strengthen the life sciences sector, Chancellor Rachel Reeves said during meetings in Washington this week. “We do need to make sure that we are an attractive place for pharmaceuticals, and that includes on pricing, but in return for that, we want to see more investment flow to Britain,” Reeves told reporters.

Recent ABPI report, ‘Creating the conditions for investment and growth’, The UK’s pharmaceutical industry is integral to both the country’s health and growth missions, contributing £17.6 billion in direct gross value added (GVA) annually and supporting 126,000 high-skilled jobs across the nation. It also invests more in research and development (R&D) than any other sector. Yet inward life sciences foreign direct investment (FDI) fell by 58per cent, from £1,897 million in 2021 to £795 million in 2023, while pharmaceutical R&D investment in the UK lagged behind global growth trends, costing an estimated £1.3 billion in lost investment in 2023 alone.

Keep ReadingShow less